included patients. Marsh classification was applied to interpret the biopsy results. We then verified different multiples of Upper Limits of Normal (ULN) IgA tTG against the D2 biopsy results.

Results The total number of adult patients who had positive serology in the study period was 214. After applying the exclusion criteria, D2 biopsies of 58 patients were studied. The age range was 17 to 89 (mean 53.46, median 57). Male female ratio was 23:35. 47 of these patients had positive D2 biopsies (Marsh 2 or above), 3 patients had biopsies consistent with Marsh 1. Positive Predictive Value (PPV) for positive tTG taking different multiples of ULN was as follows.

Abstract PWE-032 Table 1

PPV	Marsh 2 and above	Marsh 1 and above
1XULN	0.827 (48/58)	0.879 (51/58)
5XULN	0.937 (30/32)	0.968 (31/32)
10XULN	0.90 (18/20)	0.95 (19/20)
>128	1 (12/12)	1 (12/12)

Conclusions The current Gold standard for diagnosis of Coeliac disease is a positive D2 biopsy. This initial study shows that locally agreed cut off for positive serology can be accepted as diagnostic and the need for OGD and D2 biopsies could be avoided. Potentially this could reduce delays in diagnosis and allow patients to commence a gluten free diet more quickly.

PWE-033 ASSESSING GFD ADHERENCE USING URINE GLUTEN IMMUNOGENIC PEPTIDES IN COELIAC DISEASE: FIRST UK PILOT STUDY

¹Anupam Rej*, ¹Elisabeth Baggus, ²Graeme Wild, ¹David Sanders. ¹Academic Unit Of Gastroenterology, Royal Hallamshire Hospital, Sheffield, UK; ²Department of Immunology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield

10.1136/gutjnl-2019-BSGAbstracts.320

Introduction Adherence to a gluten free diet (GFD) is essential, as poor adherence can lead to persistent villous atrophy and subsequent complications of coeliac disease. We have previously shown¹ that non-invasive markers of adherence have a poor sensitivity in comparison to the gold standard of duodenal biopsy. As a result of this, we assessed the novel technique of gluten immunogenic peptides (GIP) in the urine.

Methods Patients with coeliac disease both new diagnosis and those referred to secondary care for further evaluation of dietary adherence/disease remission were assessed from September 2018 to December 2018. Patients were tested for GIP using a rapid immunochromatographic test, following the collection of mid-stream urine samples. All patients were also tested for tissue transglutaminase (IgA-TTG) and endomysial antibodies (IgA-EMA) via blood tests. At least 4 duodenal biopsies were taken from D2 and at least one biopsy from the duodenal bulb, with the presence/absence of villous atrophy used to determine sensitivities of the tests.

Results 17 patients were recruited (n=12 female, 71%), median age 52 years (range 25–74 years), median duration of GFD 96 months (0–840 months). 2 patients were newly

diagnosed CD, 15 patients were established diagnosis of CD. Table 1 outlines the sensitivity and specificity of GIP, IgA-TTG and IgA-EMA.

Conclusions Urine GIP testing was not superior to IgA-TTG or IgA-EMA. Further data is required to assess this modality as a predictor of villous atrophy and adherence before this can be used in clinical practice.

Abstract PWE-033 Table 1 | Comparison of GIP, TTG and EMA

	Sensitivity% (CI)	Specificity% (CI)	Positive predictive value% (CI)	Negative predictive value% (CI)
GIP	66.7 (24.1–94.0)	63.6 (24.1–94.0)	50.0 (17.4–82.5)	77.7 (40.1–96.1)
IgA-TTG	40.0 (7.3–83.0)	100.0 (67.9–100.0)	100.0 (19.8–100.0)	78.6 (48.8–94.3)
IgA-EMA	40.0 (7.3–83.0)	100.0 (67.9–100.0)	100.0 (19.8–100.0)	78.6 (48.8–94.3)

REFERENCE

1. Lau M, Mooney P, White W, et al. The Role of A Point of Care Test, Simtomax, in Predicting Histological Remission in Coeliac Disease on A Gluten Free Diet. *Gut* 2016;**65**:A166-A167.

PWE-034 SHOULD WE BE DIAGNOSING COELIAC DISEASE IN THE ELDERLY?

¹Lauren Marks, ¹Anupam Rej*, ¹Matthew Kurien, ¹Michael Rees, ²Simon Cross, ³Marios Hadjivassiliou, ¹David Sanders. ¹Academic Unit of Gastroenterology, Royal Hallamshire Hospital, Sheffield, UK; ²Department of Histopathology, Royal Hallamshire Hospital, Sheffield, UK; ³Department of Neurology, Royal Hallamshire Hospital, Sheffield, UK

10.1136/gutjnl-2019-BSGAbstracts.321

Introduction Coeliac disease (CD) is common, but is underdiagnosed in the elderly due to lack of physician awareness and heterogeneity of presentation. We aimed to establish whether there has been a change in the diagnosis of CD in the elderly (over 65 years old) from 1990 until present day, as well as the clinical and histopathological features of CD in old vs. young adults.

Methods Newly diagnosed CD patients were prospectively recruited from the Coeliac Specialist Clinic at the Royal Hallamshire Hospital, Sheffield, between 2008 and 2017. All patients had villous atrophy (VA) on biopsy, positive coeliac serology (IgA-tissue transglutaminase and IgA-endomysial antibodies) and compatible Human Leukocyte Antigen (HLA) typing. Additionally, patients were retrospectively identified from 1990 to 2008 to determine the trend in elderly CD diagnostic frequency over time.

Results 1605 patients with CD were recruited (n=644 prospectively, n=961 retrospectively). Of these, 208 patients (13.0%) were diagnosed over the age of 65 years between 1990 and 2017. The proportion of elderly CD diagnoses increased from 0% (n=0/11) in 1990–1991 to 18.7% (n=41/232) in 2016–2017 (p<0.001). The male to female ratio decreased with increasing diagnostic age from 1.71:1 in the 18–34 age group to 1.02:1 in the over 65 age group (p<0.001). Younger patients more commonly presented with fatigue (p<0.001) and gastrointestinal symptoms including diarrhoea (p=0.005), abdominal pain (p=0.019), and IBS-type symptoms (p=0.008), as seen in table 1. Older people